Optibrium develops intuitive software for small molecule design, optimization, and data analysis. Cerella™, the company’s proven AI, guides successful drug discovery, generating valuable insights from your data, whilst Inspyra™ combines your expert chemistry knowledge with the exploratory power of generative methods to create, evaluate and optimize novel compound ideas. Optibrium’s StarDrop™ provides a suite of integrated software with a highly visual and user-friendly interface enabling a seamless flow from the latest data through to predictive modelling and decision-making regarding the next round of synthesis and research.
Optibrium was founded in 2009 and is headquartered in Cambridge, UK, with a US subsidiary, Optibrium Inc., based in Cambridge, MA. The company works closely with over 180 customers and collaborators worldwide, including leading global pharma, biotech, agrochemical and flavouring companies and not-for-profit and academic groups. The company continues to develop new products and research novel technologies to improve the efficiency and productivity of the drug discovery process.